Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Datopotamab deruxtecan + pembrolizumab +/- platinum chemotherapy in advanced/metastatic NSCLC
NCT04526691Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting Toxicities and Treatment-emergent Adverse Events. Started Sep 2020; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04526691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526691.